What is the Need for Prostatic Biomarkers in Prostate Cancer Management?
Discriminating patients with a low risk of progression from those with lethal prostate cancer is one of the main challenges in prostate cancer management. Indeed, such discrimination is essential if we aim to avoid overtreatment in men with indolent disease and to improve survival in those men with lethal disease. We are reporting on the current literature on such prognostic tools that are now available, their clinical role and their limitations in individualizing care. There is an urgent need to incorporate such genomic tools into new platform-based clinical trial structures to further develop and validate prognostic and predictive biomarkers and provide prostate cancer patients with an effective and cost-efficient access to new drugs in the setting of personalized treatment.
Department of Urology, Inselspital, Bern University Hospital, University of Bern, Anna Seiler Haus, CH-3010, Bern, Switzerland, martin.spahn@insel.ch.
Martin
M
Spahn
Silvan
S
Boxler
Steven
S
Joniau
Marco
M
Moschini
Bertrand
B
Tombal
R Jeffrey
RJ
Karnes
D014408:Biomarkers, Tumor / Q000032:analysis / Q000235:genetics; D018450:Disease Progression; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000737:chemistry / Q000235:genetics / Q000628:therapy*; D059016:Tumor Microenvironment
D014408:Biomarkers, Tumor